Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and laboratory relevance of JAK2 V617F and BCR-ABL co-existence in Philadelphia positive CML patients.

Pakistan journal of pharmaceutical sciences - 1 Nov 2021

Ahmad Nasir, Qayum Saima, Jameel Abid, Ali Asif, Siraj Sami, Ali Johar, Yousafzai Yasar Mehmood

Abstract excerpt

Chronic Myeloid Leukaemia (CML) is characterized by BCR-ABL1 mutation. A number of research studies have published reports of concomitant JAK2-V617F mutation in BCR-ABL positive Chronic Myeloid Leukaemia. This study aims to investigate the frequency of JAK2-V617F mutation in BCR-ABL positive CML cases. After approval from ethical committee, participants were enrolled in the study. A total of 103 samples from CML...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxyurea

Share to Janus Kinase 2

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation Rate

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Identifiers

PMID: 35039265

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and laboratory relevance of JAK2 V617F and BCR-ABL co-existence in Philadelphia positive CML patients.PMID 35039265Read ↗

Co-occurrence of JAK2-V617 F mutation and BCR::ABL1 translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combinationSemantic proximity Read ↗

Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: Is there a correlation?Semantic proximity Read ↗

JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.Semantic proximity Read ↗

[Investigation of Laboratory and Clinical Feature in the Patients with Myeloproliferative Neoplasm Co-expression of BCR-ABL1 and JAK2 V617F].Semantic proximity Read ↗

JAK2 kinase inhibitors and myeloproliferative disordersSemantic proximity Read ↗

Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.Semantic proximity Read ↗

Study on the Clinical Significance of JAK2V617F Allele Burden in Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.Semantic proximity Read ↗

Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.Semantic proximity Read ↗

Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation.Semantic proximity Read ↗

JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia.Semantic proximity Read ↗

The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.Semantic proximity Read ↗

Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.